{
    "clinical_study": {
        "@rank": "13461", 
        "acronym": "Shockomics", 
        "arm_group": [
            {
                "arm_group_label": "Hemorrhagic Shock", 
                "description": "Hypovolemic shock characterized by:\nHypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.\nRapid loss of significant amount of blood\nLactate levels > 2 mmol/L"
            }, 
            {
                "arm_group_label": "Cardiogenic shock", 
                "description": "State of inadequate circulation of blood because of ventricular failure due to acute cardiac conditions, concomitant presence of:\nHypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.\nNeed for a continuous infusion of inotropic drugs\nCardiac Index <1.8 L/min/m2 without inotropic drugs or <2.2 L/min/m2 with inotropic drugs\nSigns of reduced heart function\nCardiac overload or altered left/right ventricular function"
            }, 
            {
                "arm_group_label": "Septic shock", 
                "description": "Septic shock is defined as sepsis-induced hypotension, defined as systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.\nOnly community medical acquired sepsis with a sepsis onset within 48 hours from hospital admission (i.e. different from nosocomial infection).\nLactate levels > 4 mmol/L."
            }, 
            {
                "arm_group_label": "control group", 
                "description": "The control group will consist on:\n5 healthy blood donors: serving only for the purposes of obtaining reference values for proteomics analysis\na cohort of 20 patients hospitalized for sepsis OR cardiac syndromes not developing shock: will be recruited from patients admitted to the hospital during the study period. The clinical status of the patients will be assessed during hospitalization to ascertain shock and AHF development. Shock development will be an exclusion criteria."
            }
        ], 
        "biospec_descr": {
            "textblock": "whole blood, serum, urine"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The relationship between shock, ischemia and reperfusion (I/R) injury, hemodynamic\n      instability, systemic inflammatory response syndrome and multiorgan failure has been\n      extensively investigated, but there is no consensus on the trigger mechanisms of tissue\n      injury at the molecular level.\n\n      Current therapies are targeted to reduce symptoms of shock and multiorgan damage but they\n      are unable to act at the \"beginning of the cascade\", because of the lack of a model\n      explaining the molecular basis of shock induced tissue injury and ensuing organ damage.\n\n      The present observational study is aimed at identifying the molecular triggers of acute\n      heart failure (HF) induced by shock and to identify inflammatory mediators and markers that\n      are activated in shock, with a particular emphasis on the role of uncontrolled proteolytic\n      activity."
        }, 
        "brief_title": "Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Heart Failure", 
            "Shock"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Shock"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  For patients in septic shock, Severity: SOFA score > 8\n\n          -  For patients in cardiogenic shock, Severity: SOFA score > 8\n\n          -  First blood sample available within 12 hours from admission to the ICU.\n\n          -  Only community medical acquired septic shock. We include patients with shock symptoms\n             and shock diagnosis occurring within the first 48 hours from hospital admission\n\n          -  Informed Consent available\n\n        Exclusion Criteria:\n\n          -  Risk of rapidly fatal illness and death within 24 hours\n\n          -  Patients already enrolled in other studies\n\n          -  N > 4 units of red blood cells transfused\n\n          -  Patients treated with plasma or whole blood\n\n          -  Active hematological malignancy\n\n          -  Active cancer\n\n          -  Immunodepression, including transplant patients: HIV+, constitutive immune system\n             deficiency, immunosuppressive therapy, systemic corticosteroids (aerosols allowed)\n\n          -  Patients with pre-existing end stage renal disease needing renal replacement therapy\n             (RRT). The introduction of continuous veno-venous hemofiltration (CVVH), from the day\n             of admission onward is allowed.\n\n          -  Cardiac surgery patients\n\n          -  Cirrhosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "All the patients admitted to ICU"
            }
        }, 
        "enrollment": {
            "#text": "115", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141607", 
            "org_study_id": "FP7#602706", 
            "secondary_id": "602706"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "shock", 
            "heart failure", 
            "inflammation", 
            "biomarkers", 
            "cardiovascular instability", 
            "metabolic pathways", 
            "proteolysis"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "EU project website", 
            "url": "http://www.shockomics.org"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Daniel De Backer, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "Department of Intensive Care, Erasme University Hospital"
                }, 
                "investigator": {
                    "last_name": "Daniel De Backer, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ricard Ferrer Roca, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Servei de Medicina Intensiva, Hospital Universitari M\u00fatua Terrassa"
                }, 
                "investigator": {
                    "last_name": "Ricard Ferrer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Karim Bendjelid, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Geneva", 
                        "country": "Switzerland"
                    }, 
                    "name": "Intensive Care Division, Geneva University Hospitals"
                }, 
                "investigator": {
                    "last_name": "Karim Bendjelid, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_groups": "4", 
        "official_title": "Multiscale Approach to Describe the Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock", 
        "other_outcome": {
            "description": "Patients discharged after a shock episode have high morbidity and mortality rates, and evidences indicate that physiological condition is restored only after several months. The blood sample will be collected only in patients in healthy conditions, reporting no re-hospitalization associated to shock sequelae during the follow up.", 
            "measure": "Long term effects of AHF in survivors assessed by changes in omics markers", 
            "safety_issue": "No", 
            "time_frame": "at about 100 days from ICU admission and enrollment"
        }, 
        "overall_contact": {
            "email": "manuela.ferrario@polimi.it", 
            "last_name": "Manuela Ferrario, MS, PhD"
        }, 
        "overall_official": {
            "affiliation": "Hospital Universitari M\u00fatua Terrassa", 
            "last_name": "Ricard Ferrer Roca, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Switzerland: Institutional Review Board", 
                "Spain: Institutional Review Board", 
                "Belgium: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The clinical endpoint will be Acute Heart Failure (AHF), assessed by a pool of measures/estimates of cardiac function and filling pressures, based on cardiac output monitoring, inotropic drugs requirements, left and right ventricles assessment using echocardiography.\nThe molecular biomarkers changes will be evaluated by means of proteomics, transcriptomics and metabolomics analysis of blood samples collected at the ICU admission and within 48hr after admission.", 
            "measure": "Progression/occurrence of acute heart failure and changes in omics markers in acute phase of shock", 
            "safety_issue": "Yes", 
            "time_frame": "within 48 hr after admission in ICU (acute phase of shock)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141607"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The clinical endpoints will be:\nThe Acute Heart Failure (AHF) assessed by a pool of measures/estimates of cardiac function and filling pressures, based on cardiac output monitoring, inotropic drugs requirements, left and right ventricles assessment using echocardiography.\u2028AHF will be at evaluated within 7 days after ICU admission.\nMechanical ventilation (MV)-free days or organ support (vasopressor, continuous renal replacement therapy (CRRT), etc.) free-days\nSurvival to ICU\nPrognosis at discharge from the ICU (objective - dead or alive, morbidities - and subjective)\nPrognosis at discharge from the hospital (objective - dead or alive, morbidities - and subjective).\nThe changes in molecular biomarkers will be evaluated by means of proteomics, transcriptomics and metabolomics analysis of blood samples collected within 7 days after ICU admission", 
            "measure": "Progression/Occurence of Acute Heart Failure and changes in omics markers in survivors", 
            "safety_issue": "Yes", 
            "time_frame": "within 7 days after admission in ICU (patient stabilization)"
        }, 
        "source": "Shockomics Consortium", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shockomics Consortium", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}